𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Selection of initial therapy for renal cell carcinoma

✍ Scribed by Jean B. Dekernion; Eliahu Mukamel


Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
883 KB
Volume
60
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Complete surgical excision is the only effective method of treatment for renal cell carcinoma (RCC) and patients with extensive regional or distant metastases are incurable by any means. Accurate preoperative staging is therefore of critical importance, and computerized tomography and magnetic resonance imaging are the most accurate staging modalities. The traditional operative procedure for RCC has been the radical nephrectomy with excision of Gerota's fascia and its contents, resulting in a 60% to 70% 5-year survival of patients with localized tumors (T1-2 and N0 and M0). Extensive lymphadenectomy has not appreciably improved the cure rate. Indeed, less aggressive surgery has been recently proposed by some authors, based on the excellent results achieved after partial nephrectomy or for tumors in solitary kidneys, with survival after partial nephrectomy or enucleation similar to that after radical nephrectomy. Preoperative adjuvants such as angioinfarction or radiotherapy have not increased survival or local tumor control, and no regional or systemic postoperative adjuvant has proven to be of value. Until further data is accumulated, radical nephrectomy remains the treatment of choice for localized RCC.


πŸ“œ SIMILAR VOLUMES


Sequential therapy in renal cell carcino
✍ Bernard Escudier; Marine Gross Goupil; Christophe Massard; Karim Fizazi πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 117 KB πŸ‘ 1 views
Prognostic relevance of the mTOR pathway
✍ Allan J. Pantuck; David B. Seligson; Tobias Klatte; Hong Yu; John T. Leppert; La πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 980 KB

## Abstract ## BACKGROUND. The mammalian target of rapamycin (mTOR) pathway is up‐regulated in many human cancers, and agents targeting the mTOR pathway are in various stages of clinical development. The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway

Pulmonary Sarcoidosis Following Interfer
✍ Ehtesham A. Abdi; Gia-Khanh Nguyen; Roberta N. Ludwig; William J. Dickout πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 663 KB

A 57-year-old woman developed pulmonary sarcoidosis during therapy with interferon /3 for advanced renal cell carcinoma metastatic to mediastinal lymph nodes. The possible role of interferon /3 in the pathogenesis of sarcoidosis in this patient is discussed.